Cost Management Insights: SG&A Expenses for Biogen Inc. and Perrigo Company plc

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Biogen Inc. and Perrigo Company plc, two industry giants, have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Biogen's SG&A expenses have seen a steady increase, peaking in 2021 with a 38% rise from 2014. This reflects their aggressive investment in marketing and administrative capabilities. Conversely, Perrigo's expenses have been more volatile, with a notable 89% increase from 2014 to 2023, indicating strategic shifts and potential restructuring efforts. Understanding these trends provides valuable insights into each company's operational focus and market positioning. As the pharmaceutical industry continues to face challenges, these insights are pivotal for stakeholders aiming to navigate the complexities of cost management.